69959-88-2

Basic information

• Product Name: 2-bromo-N,2-dimethyl-propanamide
• Synonyms: 2-bromo-N,2-dimethyl-propanamide;N,2-Dimethyl 2-bromopropanamide;N-Methyl 2-bromoisobutyramide;2-Bromo-N-methylisobutyramide;2-Bromo-2,N-dimethyl-propionamide
• CAS NO: 69959-88-2
• Molecular Formula: C₅H₁₀BrNO
• Molecular Weight: 180.04
• Product Categories: blocks;Bromides;Carboxes
• Mol File: 69959-88-2.mol
• Article Data: 6

Chemical Properties

• Melting Point: 38-39°C
• Boiling Point: 256.7°C at 760 mmHg
• Flash Point: 109.1°C
• Appearance: /
• Density: 1.382g/cm³
• Vapor Pressure: 0.0152mmHg at 25°C
• Refractive Index: 1.473
• Storage Temp.: Keep Cold
• CAS DataBase Reference: 2-bromo-N,2-dimethyl-propanamide(CAS DataBase Reference)
• NIST Chemistry Reference: 2-bromo-N,2-dimethyl-propanamide(69959-88-2)
• EPA Substance Registry System: 2-bromo-N,2-dimethyl-propanamide(69959-88-2)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 69959-88-2(Hazardous Substances Data)

Usage

General Description

2-bromo-N,2-dimethyl-propanamide is a chemical compound with the molecular formula C5H10BrNO. It is a derivative of propanamide with a bromine atom attached to the 2-position and two methyl groups attached to the nitrogen atom. 2-bromo-N,2-dimethyl-propanamide is used in organic synthesis and pharmaceutical research as a building block for the synthesis of various biologically active molecules. It is also employed as an intermediate in the production of pharmaceuticals and agrochemicals. Due to its potential biological activities, 2-bromo-N,2-dimethyl-propanamide is of interest for further study in drug discovery and development.

InChI:InChI=1/C5H10BrNO/c1-5(2,6)4(8)7-3/h1-3H3,(H,7,8)

Upstream product

• 20469-89-0 2-bromo-2-methylpropionyl chloride 
• 74-89-5 methylamine 
• 20769-85-1 2-bromoisobutyric acid bromide 
• 593-51-1 methylamine hydrochloride 

Downstream Products

• 91306-18-2 2-acetonyl-3,5,5-trimethyl-2-phenyloxazolidin-4-one 
• 88876-33-9 2-(1-bromo-1-methylethyl)-3,5,5-trimethyl-2-oxazolidin-4-one 
• 1101897-62-4 N,2,2-trimethyl-3-phenylpropanamide 
• 128966-00-7 2-(2,6-Dimethyl-phenoxy)-2,N-dimethyl-propionamide 
• 128966-02-9 2-(2-Iodo-phenoxy)-2,N-dimethyl-propionamide 
• 128966-01-8 2-(2-Chloro-phenoxy)-2,N-dimethyl-propionamide 
• 128965-95-7 2,N-Dimethyl-2-phenoxy-propionamide 
• 88876-37-3 2,N-dimethyl-2-methylaminopropionamide 
• 128965-91-3 α-(4-chloro-phenoxy)-isobutyric acid methylamide 
• 1428902-75-3 C₂₈H₃₉N₇O₃ 

Relevant articles and documents

Steric Limits in the Reactions of Amines with in Situ Generated α-Lactams: The Synthesis of Extremely Sterically Hindered Tertiary Amines

-

PHOSPHOINOSITIDE 3-KINASE INHIBITOR COMPOUNDS AND METHODS OF USE

Compounds of Formulas Ia-d where X is S or O, mor is a morpholine group, and R3 is a monocyclic heteroaryl group, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for modulating the activity of lipid kinases including PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula Ia-d for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed. [Insert Formula Ic and Id]

PHARMACEUTICAL COMPOUNDS

Fused pyrimidines of formula (I); wherein A represents a thiophene or furan ring; n is 1 or 2; R1 is a group of formula (II); wherein m is 0 or 1; R30 is H or C1-C6 alkyl; R4 and R5 form, together with the N atom to which they are attached, a 5- or 6-membered saturated N-containing heterocyclic group which includes 0 or 1 additional heteroatoms selected from N, S and O, which may be fused to a benzene ring and which is unsubstituted or substituted; or one of R4 and R5 is alkyl and the other is a 5- or 6-membered saturated N-containing heterocyclic group as defined above or an alkyl group which is substituted by a 5- or 6-membered saturated N-containing heterocyclic group as defined above; R2 is selected from formula (a); wherein R6 and R7 form, together with the nitrogen atom to which they are attached, a morpholine, thiomorpholine, piperidine, piperazine, oxazepane or thiazepane group which is unsubstituted or substituted; and formula (b); wherein Y is a C2-C4 alkylene chain which contains, between constituent carbon atoms of the chain and/or at one or both ends of the chain, 1 or 2 heteroatoms selected from O, N and S, and which is unsubstituted or substituted; and R3 is an indazole group which is unsubstituted or substituted; and the pharmaceutically acceptable salt thereof have activity as inhibitors of P13K and may thus be used to treat diseases and disorders arising from abnormal cell growth, function or behaviour associated with P13 kinase such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine disorders and neurological disorders. Processes for synthesizing the compounds are also described.